Elevated Immunoglobulin G as a Predictor of Progression to Severe Lung Disease in Cystic Fibrosis: A Longitudinal Cohort Study
<b>Background:</b> Elevated immunoglobulin G (IgG) levels are associated with worse lung function and disease severity in people with cystic fibrosis (PwCF). This study evaluated whether elevated IgG levels-defined as values above the 97.5th percentile (Z-score ≥ 1.96 standard deviations above the mean)-can predict progression to severe lung disease. <b>Methods:</b> A retrospective cohort study of children and adults with CF at a single-center clinic was performed. Patients with elevated baseline IgG Z-scores were compared to those with normal or low IgG levels. Progression to severe lung disease was defined as % predicted FEV<sub>1</sub> < 40%, referral for lung transplantation, or death. Kaplan-Meier survival curves and Cox models were used to analyze clinical outcomes. A sensitivity analysis was conducted for patients aged 18 years or older. <b>Results:</b> Of 97 patients, 31 (31.9%) had elevated IgG levels. Progression to severe lung disease occurred in 14 (14.4%) patients, 12 (85.7%) of whom had elevated IgG. These patients were significantly older and had a higher prevalence of Pseudomonas aeruginosa colonization. Among adults, those with elevated IgG had lower baseline % predicted FEV1 and greater annual lung function decline. Elevated IgG was independently associated with progression to severe lung disease (adjusted hazard ratio [aHR]: 9.8; 95% CI: 1.9-48.6), even after adjusting for Pseudomonas colonization and annual % predicted FEV1 decline. <b>Conclusions:</b> Elevated IgG was associated with progression to severe lung disease in PwCF and correlated with older age, Pseudomonas colonization, and-in adults-lower baseline lung function and faster decline. These findings highlight elevated serum IgG as a meaningful prognostic biomarker for identifying high-risk PwCF who may benefit from closer monitoring and earlier intervention.
Authors
- Dario Prais (ORCID: https://orcid.org/0000-0002-4165-0144)
- Miri Dotan (ORCID: https://orcid.org/0000-0001-6308-0181)
- Ori Goldberg (ORCID: https://orcid.org/0009-0002-6725-8017)
- Eyal Jacobi (ORCID: https://orcid.org/0009-0006-7286-8812)
- Meir Mei‐Zahav (ORCID: https://orcid.org/0000-0002-6683-0264)
- Moshe Heching (ORCID: https://orcid.org/0000-0001-8073-3973)
- Huda Mussaffi
- Hannah Blau (ORCID: https://orcid.org/0000-0002-1986-4349)
- ختام حمادي محمود التميمي
Institutions
- Tel Aviv University (IL)
- Hebrew University of Jerusalem (IL)
- Kaplan Medical Center (IL)
- Rabin Medical Center (IL)
- Schneider Children's Medical Center (IL)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2025-06-18
- DOI
- https://doi.org/10.3390/jcm14124331
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.52